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ABSTRACT  
 
Apoptosis is an important area of research because of its role in keeping a mature 
multicellular organism's number of cells constant hence, ensuring that the organism does 
not have cell accumulation that may transform into cancer with additional hallmarks. 
Firstly, we have carried out sensitivity analysis on an existing mitochondria-dependent 
mathematical apoptosis model to find out which parameters have a role in causing 
monostable cell survival i.e., malfunction in apoptosis. We have then generated three 
healthy cell models by changing these sensitive parameters while preserving bistability 
i.e., healthy functioning. For each healthy cell, we varied the proapoptotic production 
rates, which were found to be among the most sensitive parameters, to yield cells that 
have malfunctioning apoptosis. We simulated caspase-3 activation, by numerically 
integrating the governing ordinary differential equations of a mitochondria-dependent 
apoptosis model, in a hypothetical malfunctioning cell which is treated by four potential 
treatments, namely: (i) proteasome inhibitor treatment, (ii) Bcl-2 inhibitor treatment, (iii) 
IAP inhibitor treatment, (iv) Bid-like synthetic peptides treatment. The simulations of the 
present model suggest that proteasome inhibitor treatment is the most effective treatment 
though it may have severe side effects. For this treatment, we observed that the amount of 
proteasome inhibitor needed for caspase-3 activation may be different for cells in 
individuals with a different proapoptotic protein deficiency. We also observed that 
caspase-3 can be activated by Bcl-2 inhibitor treatment only in those hypothetical 
malfunctioning cells with Bax deficiency but not in others. These support the view that 
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molecular heterogeneity in individuals may be an important factor in determining the 
individuals’ positive or negative responses to treatments. 
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Introduction 
 
Chemotherapy resistance is an important problem in cancer treatments. A specific cancer 
chemotherapy that is used on patients whose tumors have similar histopathology may 
have very different responses. Oncologists suspect that subsets of patients that respond 
positively to a chemotherapy are hidden in larger groups of resistant cases. Genetic and 
molecular heterogeneity may be the cause of those subsets.
1
 The presence or absence of, 
or more specifically, the quantity of a biological molecule e.g., DNA, RNA, protein and 
other metabolites which indicate whether the individual is healthy or has a disease is a 
biomarker. Therefore, assessment of biomarkers can unravel this genetic and molecular 
heterogeneity and may be utilized to determine the type and the intensity of 
chemotherapy method to treat a patient. Mathematical modeling and computations may 
facilitate the decision of the chemotherapy method to be used because just experience 
may not be enough because of the complex nature of cancer.  
 
The beneficial effects of chemotherapy drugs can be mitotic catastrophe, apoptosis or 
prolonged cell cycle arrest. Hence, defects in apoptotic mechanisms may be a reason for 
chemotherapy resistance. The mitochondria-dependent apoptotic pathway is the major 
apoptotic pathway which is utilized by chemotherapeutic drugs.
2
 Depending on which 
tissue they belong to, there are two types of cells for apoptosis: Type I and Type II. If the 
apoptotic signaling pathway bypasses mitochondria then these are Type I cells and if not, 
these are called Type II cells.  
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A mathematical model for mitochondria-dependent apoptosis, in which bistability 
emerges as healthy functioning of the Type II cells was proposed by Bagci et al.
3
 In this 
model, the extracellular apoptotic stimulus (Fas Ligand) results in cytochrome c (cyt c) 
release from the mitochondria and caspase-3 activation which is the executioner enzyme 
for apoptosis. For simplicity, the model excluded the reactions before caspase-8 
formation. The detailed descriptions of the model can be found in Model and Methods 
section of the study by Bagci et al.
3
  
 
The biochemical mechanism of apoptosis is studied extensively because of the 
importance of keeping the number of cells in the mature organism balanced in response 
to pro- or anti-apoptotic stimuli.
4
 In healthy tissues, cell number stays constant when the 
rate of cell proliferation is equal to the rate of cell death. However, in malfunctioning 
apoptosis, the rate of cell proliferation can be higher (lower) than the rate of cell death 
and the number of cells increases (decreases). The total number of cells in a tissue 
increases in tumorigenesis whereas it decreases in neurodegenerative disorders (e.g. 
Parkinson’s disease and Alzheimer’s disease). 
 
In this study, by healthy cells, we mean the cells without apoptosis malfunction prior to 
any treatment. Healthy cells are converted to cells with apoptosis malfunction by 
decreasing the proapoptotic protein production rates in the model. We call these cells 
“hypothetical malfunctioning cells”. However, these hypothetical malfunctioning cells 
can not represent all the tumor cells as some of the tumor may have apoptosis rates that 
are considerably higher than that of normal cell.
5,6
 The hypothetical malfunctioning cells 
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are then treated in silico by four different treatment methods. The cells are predicted to be 
resistant to treatment if they do not undergo apoptosis. On the other hand, they are 
predicted to be sensitive to the treatment if apoptosis is induced. 
 
After pioneering studies by Fussenegger et al.
7
 and Eissing et al.,
8
 many apoptosis models 
have been published (see review by Salvioli et al.
9
 and other references
3, 10-28
), however, 
none of these studies focused on resistance to treatment (i.e., despite treatment, the cells 
survive due to lack of apoptosis). In treatments that target apoptotic pathways, drugs 
affecting extracellularly either activate Fas or another death signaling receptor. On the 
other hand, drugs affecting intracellularly upregulate proapoptotic proteins and/or 
downregulate antiapoptotic proteins. In this study, we focused on intracellular affecting 
treatments. The results herein suggest that the type of potential treatment and the identity 
of the deficient proapoptotic protein determine whether apoptosis will be induced in a 
hypothetical malfunctioning cell. Therefore, the results suggest that the reason of 
different outcomes of a treatment in different people may be genetic variations in their 
cells that can be observed through their possible biomarkers for apoptosis namely, 
production rates of proapoptotic proteins
4
. 
 
The previous simulations by Bagci et al.
3
 predicted a pathological state in which cells 
will exhibit a monostable cell survival if the degradation rate constant (expression rate 
constant) of the proapoptotic protein Bax is above (below) a threshold value. On the other 
hand, with suitable values of rate constants, the model predicts bistability with a suitable 
threshold of apoptotic stimulus for apoptosis. We used a mathematical model that was 
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originally proposed by Bagci et al.
3
 to shed light on resistance to treatments because this 
model successfully predicts the correct functioning (bistable, healthy cell) and 
malfunctioning (monostable, unhealthy cell) of apoptosis. We have also used a modified 
version of this model in our study. Herein, it is assumed that all pathways other than 
those related to apoptosis remain unchanged, and therefore a change in apoptosis will 
lead to a change in homeostasis of the number of cells. In this article, we first present the 
sensitivity analysis to determine the most sensitive parameters to caspase-3 activation. 
Then, we summarize the results of the sensitivity analysis performed on the model 
parameters. This is followed by presenting the simulations of four hypothetical potential 
treatments i.e., the proteasome inhibitor treatment, Bcl-2 and IAP inhibitors treatment 
and Bid-like synthetic peptides treatment of which proteasome inhibitor treatment is 
predicted to be the most effective. The aims of the in silico experiments were (i) to gain 
insights for the role of molecular heterogeneity in resistance to treatment for malfunction 
in apoptosis and (ii) to check if the underlying reaction mechanisms should be modified 
and/or new reactions should be added into the pathway and (iii) to check if the parameter 
values used in the existing model should be known within a narrow range (i.e., sensitive) 
so that the resulting model and parameters could be used in guiding treatments. The 
results support the view that molecular heterogeneity among individuals may be a reason 
for varied responses to treatments. As for the second and third aims, we have found the 
reactions which are important and the parameters which should be known within a 
narrow range for the present model. We have also compared the experimental methods of 
Kim et al.
29
 with the theoretical predictions of our modified model. We also compared the 
predictions of our model with the experimental results compiled by di Pietro et al.
30
 from 
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several databases. It should be emphasized that our focus in this study is on malfunction 
in apoptosis and resistance to treatments for it and not the much more complicated 
problem, chemotherapy resistance to cancer. 
 
Methods 
 
In the model proposed in the reference
3
, the rate constants ensure bistability in apoptotic 
response where initial concentrations smaller than threshold values for caspases lead to 
cell survival and higher initial concentrations lead to apoptosis. The chemical reactions 
and physical interactions of the proteins involved in the apoptotic pathways of this model 
are presented in Supplementary Materials Figure S1 and Table S1 for easy reference. As 
mentioned in the previous section, sensitivity analysis is performed to determine the 
parameters that may have a role in malfunctioning apoptosis and resistance to treatment. 
Out of those parameters that are found to be sensitive (ten of them) (See Table 1), we 
have varied arbitrarily chosen four of them among the benchmark parameter values given 
in reference
3
 to determine whether the system is robust to parameter variations. For this 
purpose we obtained two additional parameter sets each representing cells belonging to a 
healthy  individual (Table 2). The benchmark parameters are varied so as to preserve the 
bistable character of the system. Therefore, each parameter set is bistable in response to 
apoptotic stimulus and hence represents cells of healthy individuals. We then used these 
three parameter sets to simulate four hypothetical potential treatments. We also generated 
six malfunctioning point cells around the nominal malfunctioning point cells in parameter 
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set 1 and 3 to evaluate the statistical significance of the results for the two parameter sets. 
The new parameter sets around set 1 and 3 are presented in Table 4. 
 
When mass action kinetics is applied, the reactions listed in Table S1 lead to rate 
equations in the form of nonlinear ordinary differential equations.
3
 Herein, we solved 
these equations numerically using the software XPPAUT developed by G. Bard 
Ermentrout
31
 for the simulation of the potential treatments. 
 
Modified version of mitochondria-dependent apoptosis model: 
The following degradation of caspase-3 reaction is omitted from existing mitochondria-
dependent apoptosis model: 
caspase-3 → aminoacids 
The following reactions
32
 are added to the existing mitochondria-dependent apoptosis 
model: 
  caspase-3.IAP → IAP + caspase-3ubuiquitinated      
caspase-3 ubuiquitinated → aminoacids                      
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Results and discussion 
 
Firstly, some preliminary results on nullclines, and phase plane for bistable and 
monostable dynamical system are discussed for easy reference as they are profusely used 
in the later subsections. Figure 1A illustrates the phase plane of a bistable apoptosis 
model. There are three steady states, denoted by (i), (ii) and (iii) which have zero, high 
and intermediate levels of executioner caspase (caspase-3) concentration. The steady 
state (i) is the cell survival state (zero executioner caspase concentration), (ii) is the 
possible apoptotic state and (iii) is the cell fate decision point. The steady states (i) and 
(ii) are stable because a small perturbation away from them eventually disappears. On the 
other hand, the steady state (iii) is unstable because a small perturbation away from it 
grows. The thick curves are the nullclines
33
 and their intersections are the steady state 
points.  
 
The two stable equilibrium points may bifurcate to one stable equilibrium point (i.e., 
become monostable) if a system parameter (e.g., degradation rate of caspase-3) is 
changed. The phase plane in Figure 1B is an example of this case; where the monostable 
state is cell survival. 
 
We first present the sensitivity of steady state caspase-3 concentration to the parameters 
of the model by Bagci et al.
3
 and determine those that may induce a malfunction in 
apoptosis when perturbed from their nominal values. The model is presented 
schematically in Figure S1 and the list of chemical reactions and physical interactions are 
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listed in Table S1. For parameter values, see the reference
3
. Then, we present outcomes 
for four hypothetical treatments that are obtained by simulating the model for three 
different parameter sets each representing a healthy cell. Finally, we present the 
sensitivity results and proteasome inhibitor treatment outcomes for the modified model 
(corrected for IAP – caspase-3 interactions), and also compare model predictions with 
experiments that addressed the effect of Bcl-2 and IAP inhibitors in chondrosarcoma 
cells
29
 and with experimental results compiled by di Pietro et al.
30
 from databases. 
 
Sensitivity analysis of mitochondria-dependent apoptosis model 
 
To evaluate the sensitivity of caspase-3 concentration to the parameters, we used a 
different and a much simpler method than the one used by Shoemaker and Doyle
34
 who 
have carried out sensitivity analysis on the parameters in the same model using tools from 
control engineering. However, the results of the two different approaches are in good 
agreement. Hereafter, the nominal values of the parameters are understood to be those 
given in the reference
3
 and the steady-state concentration of caspase-3 for these 
parameters corresponds to 5.4 nM. For sensitivity analysis we increased and decreased 
the values of the parameters by 100-fold and then checked how much the steady-state 
value of [caspase-3] is changed (Table 1). The following parameters are found to be 
sensitive that affect the final steady-state concentration of caspase-3: p53 concentration 
([p53]), production rate constants of pro-apoptotic proteins, Apaf-1 (ΩApaf1), procaspase-3 
(Ωproc3), procaspase-9 (Ωproc9), Bid (ΩBid), Bax (ΩBax), mitochondrial cyt c (Ωcytcmito), anti-
apoptotic proteins Bcl-2 (ΩBcl2), IAP (ΩIAP), and degradation rate constant for all the 
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proteins (kd). The same results were also observed by Shoemaker and Doyle
34
. They also 
found that steady-state concentration of caspase-3 is not sensitive to most of the 
parameters.  
 
Sensitivity analysis revealed not only the sensitive parameters but also whether an 
increase or decrease in these parameters may lead to malfunction in apoptosis. It is found 
that when the production rate constants of proapoptotic proteins are low, and production 
rate constants of antiapoptotic proteins and degradation rate constant of all proteins are 
high, the model predicts monostability with the cell survival state being the only stable 
state. Therefore, the sensitivity analysis helped us to create cells with malfunctioning 
apoptosis. These hypothetical malfunctioning cells are then treated in silico by four 
treatment types.  
 
Hypothetical treatments 
 
The roles of the sensitive parameters on malfunction in apoptosis and resistance to 
treatments in a hypothetical cell were then investigated. The simulations were carried out 
for three parameter sets representing three healthy cells which may belong to three 
different individuals (since each parameter set results in bistability) to test the robustness 
of the theoretical outcomes of the treatments. Parameter set 1 was taken as the parameter 
values used in the reference
3
. Parameter set 2 was obtained by changing the numerical 
values of production rates of IAP (ΩIAP), procaspase-9 (Ωproc9), procaspase-3 (Ωproc3) of 
set 1. Finally, parameter set 3 was obtained by changing the numerical values of 
 13 
production rates of IAP (ΩIAP), procaspase-3 (Ωproc3) and mitochondrial cyt c (Ωcytcmito) of 
set 1. These three parameter sets are given in Table 2. We note that the numerical values 
of parameters in parameter set 1 are close to those in set 2 but considerably different than 
those in set 3. The true values of these sensitive parameters are only known within a wide 
range. Even if we only take upper and lower values of these ten sensitive parameters (i.e., 
2 levels), the number of in silico experiments that has to be carried out is a very large 
value 1024 (=2
10
) to obtain all main and interaction effects.
35
 Therefore, we took only 
three of them to generate our healthy cells which may belong to three different 
individuals and yet found qualitative and quantitative differences. We note that the gene 
expression levels of caspase-3, caspase-9 and cyt c are reported to vary naturally in 
human individuals in a database that also reports certain polymorphisms in the genes.
36
 
 
In order to generate cells with malfunctioning apoptosis from each parameter set, the 
numerical value of one of the sensitive parameters was changed and then checked 
whether this cell had malfunction in apoptosis. If the result was on the affirmative, then 
we applied four potential treatments, one at a time to see if apoptosis can be achieved in 
this cell. To this end, the production rates of proapoptotic proteins were reduced to 1 % 
and 15 % of their nominal values. These proapoptotic proteins were Apaf-1, procaspase-
3, procaspase-9, Bid, Bax and mitochondrial cyt c. The criterion for malfunction in 
apoptosis in those phenotypes was either monostability (cell survival i.e., caspase-3 
concentration is zero as shown in Figure 1B) in responding to apoptotic stimulus or 
bistability with caspase-3 concentration not reaching a predetermined threshold value of 
1 nM which is only to be understood relatively hereafter. This concentration corresponds 
 14 
to approximately 2500 molecules for a cell of diameter 20 m. We notice that in most of 
the proapoptotic protein deficiencies, the model predicts malfunction in apoptosis, one of 
the hallmarks of cancer. This is in line with the observation that cancer is linked with 
suppressed levels of pro-apoptotic proteins.
37
 Note that when the production rates of 
proapoptotic proteins are reduced to 50 % of their nominal values, cells with malfunction 
in apoptosis were predicted to be unattainable in all cases for parameter sets 1 and 2 and 
for parameter set 3 except for Bid deficiency, the cells had malfunction in apoptosis (data 
not shown). 
 
The final value of the caspase-3 concentration was obtained as the steady-state solution 
of the governing differential equations using XPPAUT.
31
 At the end of the simulation 
run, if it was found that the cell is resistant to apoptosis, then we simulated the effect of 
the potential treatments described below. To this end, we made an appropriate change in 
a parameter to represent the effect of treatment and checked whether caspase-3 was 
produced. We assumed that the treatment becomes successful if caspase-3 concentration 
reached values greater than or equal to 1 nM. In those cells apoptosis may occur in a 
monostable fashion as well. This was not investigated in this work. 
 
Using the sensitivity results (Table 1), four different treatment methods, which were also 
proposed by experimentalists, and which may yield the final caspase-3 concentration 
greater than or equal to 1 nM were simulated to achieve apoptosis in the hypothetical 
malfunctioning cell: 
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1) Proteasome inhibitor treatment
38
 (simulated by reducing the degradation rate constant 
(kd) of proteins)  
2) Bcl-2 inhibitor treatment
39
 (simulated by decreasing the production rate constant of 
anti-apoptotic protein Bcl-2)  
3) IAP inhibitor treatment
39
 (simulated by decreasing the production rate constant of anti-
apoptotic protein IAP) 
4) Bid-like synthetic peptides treatment
40
 (simulated by increasing the production rate of 
proapoptotic protein Bid) 
 
The first treatment listed above which has the effect of reducing the degradation rate 
constants of the proteins might also have severe side effects because this treatment 
inhibits proteasomes that degrade proteins involved in pathways other than apoptosis as 
well and hence affecting the other functions of the cell. On the other hand, 
downregulating Bcl-2 and IAP and upregulating Bid might have less severe side effects.  
 
The predictions of the outcomes of those four potential treatments are discussed below 
and the results are presented in Tables 3-9. 
 
Possible outcomes of proteasome inhibitor treatment. 
 
Herein we checked whether apoptosis is achieved in a hypothetical malfunctioning cell, 
i.e., a cell whose steady-state concentration of caspase-3 is less than 1 nM. For this 
purpose, as a treatment, we reduced the degradation rate constant of proteins (kd) to 
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achieve apoptosis. Rate constant kd can be reduced biochemically by using a proteasome 
inhibitor.
38
 The preclinical studies have shown that proteasome inhibitor bortezomib 
induces apoptosis, and overcomes chemoresistance in several malignancy models in vitro 
and in vivo.
41
 As the proteins are degraded by the same proteasome machinery, we have 
taken all the degradation rates of the proteins to be equal to kd (0.006 s
-1
 as an 
approximate value) and decreased its value to see if caspase-3 concentration exceeds the 
threshold value of 1 nM to mimic the effect of proteasome inhibitor. When the cell is a 
hypothetical malfunctioning cell, then, the ranges of kd values within which apoptosis is 
possible are tabulated in Table 3. It is shown that as kd value becomes smaller, the steady-
state caspase-3 concentration increases in the present theoretical results (sensitivity 
results in Table 1). This functional relation was investigated using steady-state 
concentration of caspase-3 versus kd graph. This bifurcation diagram of caspase-3 with 
respect to kd is presented in Figure 2. The parameter set 1 was used for the values of the 
parameters in the rate equations except for the Apaf-1 production rate which was 
decreased by a factor of 100-fold (upper left entry in Table 3) to create a hypothetical 
malfunctioning cell. Apoptotic response was monostable apoptosis when kd was less than 
the limit point 1 (LP1) (kd = 0.006x0.07 s
-1
) or monostable cell survival when kd was 
greater than limit point 2 (LP2) (kd = 0.006x0.48 s
-1
) and bistable when kd was in 
between this interval (0.006 s
-1
 is the nominal value of kd). For the bistable case, whether 
the response results in cell survival or apoptosis depends on the initial concentration of 
caspase-3 protein. The upper solid curve in Figure 2 represents the apoptotic steady state, 
the dashed curve in the inset represents the unstable steady state (a slight increase in 
caspase-3 concentration will lead to apoptosis, whereas, a slight decrease will lead to cell 
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survival) and the horizontal lower solid line represents the cell survival steady state. The 
inset is the enlargement of the lower part of the diagram as this becomes invisible due to 
scaling. The points for steady states which were simulated are shown in circles and the 
smooth function curves were obtained using the KaleidaGraph Version 4.0 (Synergy 
Software). The caspase-3 concentration 6.7x10
-3
 nM was very low to start apoptosis 
when the value of kd at LP2 is 0.006x0.48 s
-1
. Therefore, in Table 3, we tabulated the 
range of kd values for which caspase-3 steady state concentration is above the threshold 
value of 1 nM which was obtained when kd was smaller than or equal to 0.006x0.35 s
-1
. 
The same procedure was repeated to fill in the rest of the entries in Table 3. The case 
when kd < LP1, i.e., the cells are monostable apoptotic, was not investigated in this work. 
 
In this study, inhibition of proteasomes (simulated by reducing kd) was found to induce 
apoptosis in hypothetical malfunctioning cells. Experimental studies also suggest that 
proteasome inhibitors can be used for inducing apoptosis.
38
 However, it should be noted 
that the present study does not take into account the inhibition of proteasomal 
degradation of IKB and subsequent inhibition of NF-KB which can change the 
production rates of proteins in the apoptotic pathways.
42
 
 
It can be seen in Table 3 that the overall proapoptotic protein degradation rate has to be 
decreased in different proportions for each proapoptotic protein deficiency. This 
difference may help to determine the amount of proteasome inhibitor needed to treat a 
patient. For a healthy cell, it was assumed that apoptosis is possible when kd is less than 
or equal to 0.006 s
-1
.
3
 When a cell’s Apaf-1 production rate was reduced by 100-fold, 
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while keeping the other protein production rates at their nominal values, apoptosis was 
then possible for kd range between 0 – 0.006x0.35 s
-1
. When a cell’s Bid production rate 
was reduced by the same amount, apoptosis could be achieved if kd range was 0 – 
0.006x0.88 s
-1
. Therefore, the amount of proteasome inhibitor which should be used for 
the treatment of a patient with Apaf-1 deficiency may be more than a patient with Bid 
deficiency according to the present model. To know the least amount of drug that is 
effective is important to reduce its side effects.  
 
When we analyzed the consequences of Bid deficiency in people whose Bid production 
rate was reduced to 15 % of its nominal value, it was found that the cells represented by 
parameter sets 1 and 2 are healthy, however, the cell represented by parameter set 3 have 
malfunction in apoptosis. Moreover, the kd ranges are similar in parameter sets 1 and 2 
but the ranges are significantly different in parameter set 3. To check whether variations 
in four proteins’ (IAP, procaspase-3, procaspase-9 and mitochondrial cyt c) production 
rates produce statistically significant outcome, we have generated 6 point cells that 
belong to patients from the parameter sets in Table 4 which are obtained around the 
nominal one for parameter sets 1 and 3 given in Table 3 (parameter set 2 is not included 
for it is similar to the parameter set 1) for each hypothetical impairment in the production 
levels of the pro-apoptotic proteins (column 1 in Table 5) and 90, 95, 99% confidence 
intervals for the difference in the means of the two hypothetical populations of the 
parameter sets 1 and 3 are calculated. When the production rates of proapoptotic proteins 
are decreased by 100 fold, then it is found that there is a statistical significance for Apaf-
1, procaspase-3 and procaspase-9 but no statistical significance for Bid, Bax and 
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mitochondrial cyt c. This is because the confidence intervals for the former set include 
zero within their confidence interval hence the mean values can also be equal. On the 
other hand, when the production rates are decreased by 15%, some of the mutations did 
not lead to unhealthy cells hence no confidence interval is calculated for that group and 
for those that we have calculated all the confidence intervals is found to include zero. The 
groups of cells in parameter set 1 and 3 can be considered as two groups of different 
genetic background but similar within. The statistical results suggest that parameter set 1 
group require different doses of proteasome inhibitor compared to the individuals whose 
cells can be represented by parameter set 3 if they have a drastic reduction down to 1% in 
their production rates of Apaf-1 or procaspase-3 or procaspase-9 proteins. 
 
In this study, we did not assess the degradation of proteins by lysosomes as this will 
simply shift the steady state concentrations of all the proteins in the cell downwards. 
 
Possible outcomes of Bcl-2 and IAP inhibitors treatments. 
 
In the previous treatment method, we determined the proapoptotic proteins whose 
deficiencies may result in hypothetical malfunctioning cell formation. For treatment 
purposes, we then reduced the antiapoptotic Bcl-2 and IAP production rates to induce 
apoptosis in these hypothetical malfunctioning cells with proapoptotic protein deficiency 
from Apaf-1 to cyt c (Table 6). The production rate constants of Bcl-2 and IAP can be 
reduced biochemically by introducing their hypothetical inhibitors into the medium.
39
 
Such an inhibitor for Bcl-2 is obatoclax mesylate (GX015-070)
43
 and for IAP is SMAC 
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peptide derived small compounds.
39
 Instead of including the reaction of a protein with an 
inhibitor, the same effect can also be obtained by reducing the production rate of the 
same protein. This means that if three proteins are synthesized and one of them is quickly 
inactivated by an inhibitor which binds irreversibly, then the production rate of the 
functional protein will be reduced by one third. 
 
The outcomes of treatment methods for the hypothetical malfunctioning cells wherein 
Bcl-2 and IAP inhibitors are introduced as a treatment are summarized in Tables 6 and 7, 
respectively. As for the cells whose caspase-3 concentration exceeds the threshold value 
of 1 nM, no treatment is needed (denoted by “Healthy cell” in the Tables). On the other 
hand, when the cells are hypothetical malfunctioning cells then whether the treatment 
induces apoptosis (the cells are sensitive or resistant to treatment) depends on the 
parameter set and proapoptotic protein deficiency. Reducing the production rates of Bcl-2 
or IAP may induce apoptosis. By how much amount the production rate had to be 
reduced is presented in Table 6 so that caspase-3 concentration exceeded its threshold 
value (however IAP inhibitor treatment did not induce apoptosis). For example, in Table 
6 for parameter set 1, when Bax concentration was reduced to 15 % of its nominal value, 
apoptosis was possible if the production rate of Bcl-2 was reduced to values smaller than 
3x10
-2
 x 0.10 nM/s (note that for a healthy person Bcl-2 formation rate was assumed to 
be equal to 3x10
-2
 nM/s - reference
3
). This cell is sensitive to treatment. On the other 
hand, if the hypothetical malfunctioning cells did not undergo apoptosis even with zero 
production rates of Bcl-2 and IAP, then this case is presented as “Apoptosis impossible 
(denoted by x)” in the Tables. For these cases, the steady-state caspase-3 concentration 
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was either zero, or equal to a value smaller than 1 nM and the corresponding hypothetical 
malfunctioning cells are resistant to treatment. For example, in Table 6 and parameter set 
1, when the production rate of procaspase-3 is 15 % of its nominal value, steady state 
caspase-3 concentration is 0.80 nM.  
 
The results for parameter sets 1 and 2 presented in Tables 6 and 7 show that an individual 
with a Bax production rate reduced to 15 % of its nominal value could be successfully 
treated by a Bcl-2 inhibitor but not by an IAP inhibitor. Also, Bcl-2 inhibitor therapy can 
only be effective on people with Bax deficiency (sensitive to treatment) but not on others 
(resistant to treatment). The reason for Bcl-2 inhibitor being effective on Bax deficiency 
is possibly because of the fact that Bcl-2 directly interacts with Bax (Figure S1). These 
simulation results suggest that molecular heterogeneity in patients can be a reason for 
different treatment consequences. On the other hand, these qualitative results were not 
obtained for the parameter set 3. Hence, the model is not robust to the choice of 
parameter values of ΩIAP, Ωproc9, Ωproc3, Ωcytcmito in assessing the outcomes of Bcl-2 and 
IAP inhibitors treatment methods. When Bcl-2 inhibitor treatment is employed for the 
patients whose proapoptotic protein production rates are reduced to 1% of their nominal 
values, no variations are detected between the groups of parameter set 1 and 3 and also 
within the groups of each set (Table 8). However, some differences are observed when 
the production rates are reduced to 15% of their nominal values for Bax production 
deficiency.  
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Possible outcomes of Bid-like synthetic peptides treatment. 
 
In order to induce apoptosis in hypothetical malfunctioning cells, we then increased the 
production rate of Bid in the parameter sets by three-fold. Increase in Bid production rate 
may be induced biologically by the penetration of Bid-like synthetic peptides into the 
cells by endocytosis.
40
 Apoptosis was not possible in response to Bid-like synthetic 
peptides treatment for the parameter sets 1, 2 and 3 even though the production rate of 
Bid was increased by 20-fold (Table 9).  
 
Results for modified mitochondria-dependent apoptosis model 
 
In this study, we increased the IAP production rate (ΩIAP) as large as 1000 fold and 
simulated the caspase-3 concentration. Under these conditions the caspase-3 
concentration reached a steady-state value of 1.8 nM, still above the assumed threshold 
value (1 nM). This is contrary to the expectations since at such a high value of inhibitor 
production rate, one would expect a very low caspase-3 concentration
8, 17, 32, 44-45
). 
Therefore, we modified the mitochondria dependent apoptosis model and included the 
inhibition of caspase-3 by IAP through ubiquitination and subsequent degradation by the 
proteasome. (See Methods section). The resulting model for parameter set 1 and 2 are 
again found to be bistable but monostable cell survival for parameter set 3. However, our 
modified model for this parameter set is bistable when the production rate of 
mitochondrial cyt c is increased by two-fold. Thousand-fold increase in the production 
rate of IAP did not produce cells with malfunctioning apoptosis in the existing model. 
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When the IAP degradation mechanism is modified (see Methods section) then, a 
reasonable increase in the IAP production rate has resulted in monostable cell survival.  
 
 Comparison of theoretical results with experiments. 
 
A recent experimental study
29
 focused on the effect of IAP and Bcl-2 inhibitors in 
restoring cyt c release from mitochondria to cytoplasm and apoptosis in chondrosarcoma 
cells. We used the modified model to see if we can see this effect in silico. To this end, 
we assigned a nominal production rate value of 0.06 nM/s to IAP and 0.08 nM/s to Bcl-2 
which ensured bistability. Then, we increased both production rates by six-fold so as to 
create hypothetical malfunctioning cells. Later, we simulated the effect of Bcl-2 or IAP 
inhibitors which resulted in cyt c release and caspase-3 activation which were used to 
treat cell one at a time (Figure 3). The simulation of IAP inhibition is presented in Figure 
3A. The IAP production rate is set at its nominal value (corresponds to a level in a 
healthy cell) whereas Bcl-2 production rate is set at six-fold of its nominal value. The 
model predicts cyt c release to cytoplasm and caspase-3 activation under these conditions 
in agreement with observations in the reference
29
. The simulation of Bcl-2 is presented in 
Figure 3B. Again, the model predicts cyt c release to cytoplasm and caspase-3 activation 
in agreement with the study in the reference.
29
 Hence, inhibition of either Bcl-2 or IAP is 
sufficient to restore normal apoptotic function in states where both proteins are 
constitutively upregulated. Therefore, the computations are in agreement with the 
observation that changes in more than one protein’s levels can play a role in causing 
malfunctioning of apoptosis. 
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Di Pietro et al.
30
 conducted an extensive study on Genomics, Transcriptomics, 
Proteomics, Interactomics, Oncogenomics, and Pharmacogenomics of Apoptotic 
Machinery in Homo sapiens. They report mRNA levels of proteins in apoptotic 
machinery in normal and cancer cells for 13 cancer types. We compared their findings 
related to transcriptomics of apoptotic machinery with our theoretical predictions. They 
utilized the data available in Human Transcriptome Map, NCI60 Cancer Microarray 
Project and Oncogenomics for cancer and normal tissues.
46-48
 The authors reported the 
upregulation and downregulation of gene expression when the gene is up or 
downregulated by at least three fold in a cancer tissue compared to a normal one. 
Accordingly, we increased or decreased the protein expression rates that are present in 
our model by at least three fold in the simulations and checked whether apoptosis can be 
induced with enough caspase-3 activation. The results are summarized in Table 10 where 
column number 1 lists the 13 different cancer types, column numbers 2-7 list the change 
in the levels of mRNA of proteins which are present in our model (extracted from Figure 
7A in their paper) and the last column gives our simulation results. In this table 0 denotes 
no level change, and + and – denote up and downregulation (black, red and green regions, 
respectively, in their Figure 7A). For example, for ovary cancer, caspase-3 concentration 
level predicts cell survival (0.9 nM) which corresponds to casp9, Bcl-2, Bid and Apaf-1 
expression rates remaining constant and Bax increasing by three fold in cancer cells 
compared to normal cells and only when caspase-3 expression rate is decreased by 85% 
(0.15x), do we get cell survival. Among those 13, our theoretical results predict apoptosis 
malfunctioning in six cancer types. Interestingly, out of seven types that we failed to 
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predict apoptosis malfunction, the three cancer types (pancreas, skin, thyroid cancers) 
have mutations in BRAF, CDKN2A and TP53 genes (the remaining ten cancers do not 
have these mutations) that are either not included (BRAF, CDKN2A) or not represented 
adequately (TP53, data not shown) in our model. These theoretical results suggest that 
the transcription of these three genes should be included in an apoptosis model to 
correctly predict the apoptosis malfunction. 
 
To assess the statistical significance of the prediction of deregulated apoptosis in 6 out of 
13 cancer types (since the data is taken from real patients who suffer from cancer), we 
have simulated the 729(=3
6
) combinations of  +, - or 0 (+ obtained by multiplying the 
production rate of target protein by three, - by dividing by three and zero by leaving 
unchanged) in the six target genes and found that 435 out of 729 has led to tumor 
formation.  The fact that the ratio of 6/13 is lower than the background rate 435/729, 
suggests that we might not have included all the necessary proteins into the model which 
may lead to cell accumulation and this is conjectured in the previous paragraph.  The 
expression dynamics of BRAF, CDKN2A and TP53 genes and the subsequent dynamics 
of their protein product concentrations are not exactly being understood and hence not 
included in the model. Had these been included, the prediction ratio could have been as 
high as 9/13 which is higher than the background rate. 
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Conclusion 
 
 
We have used an ODE model composed of 31 dependent variables obtained from mass-
action kinetics with 52 parameters most of which are coming from the kinetics of the 
reactions. Out of these 52 parameters caspase-3 concentration was found to be sensitive 
to 10 of them. A subset of these parameters was changed to create 3 healthy cells which 
are further changed to create hypothetical malfunctioning cells and four different in silico 
treatment methods are used on the hypothetical malfunctioning cells. It is found that the 
proteasome inhibitor treatment may be the most effective one compared to other 
treatment methods as this restores apoptosis in cells for all proapoptotic protein 
deficiencies. On the other hand, in Bcl-2 and IAP inhibitors and Bid upregulation 
treatment methods only some of the proapoptotic protein deficiencies may be treated. 
Consequently, depending on the type of the treatment and the identity of the deficient 
proapoptotic protein, apoptosis may not be induced in a hypothetical malfunctioning cell. 
It is to be noted that the response to treatments is studied by considering malfunction only 
in apoptosis but not in other pathways such as multi drug resistance gene pathway. We 
speculate that the present study is in line with the view that the reason of different 
outcomes of a chemotherapy method in different people may be their molecular 
heterogeneity that can be observed through their cancer biomarkers. Our reasoning for 
this speculation is that a problem occurring in one stage of cancer, i.e., a malfunction in 
apoptosis, can also be a factor in the overall picture of cancer progression and 
chemotherapy resistance. Hence, the effect of molecular heterogeneity in apoptosis may 
also have a role on cancer chemotherapy resistance.  
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It is argued that biological processes are highly robust to parameter changes.
49
 However, 
the detailed analysis of the existing mitochondria-dependent apoptosis model and its 
modified version has shown the parameters and the reactions that are more effective than 
others. Therefore, computational studies like these may be beneficial to help 
experimentalists to decide which interactions to study and which kinetic parameters to 
measure. 
 
The results imply that targeted treatments on one protein only i.e., Bcl-2 and IAP 
inhibitors treatments and Bid-like synthetic peptides treatment are not very effective 
except when the problem is in the targeted protein. For example, Bcl-2 inhibitor 
treatment will very likely restore apoptosis in a malfunctioning cell with a defect in its 
Bcl-2 protein but not on any other proteins. On the other hand, proteasome inhibitor 
treatment may be much more efficient since this affects all of the proteins in the model. 
This hypothesis remains to be tested by experiments. Another hypothesis to be tested by 
experiments which is raised in this study is that a treatment is not likely to be effective if 
the target protein is not close in the sequence of reactions/interactions in the pathway to 
the problematic protein. A close interaction between experimentalists and theoreticians 
may be useful to test the hypothesis arising from computations which will in turn 
improve the models to generate new hypotheses.
50
 
 
It is to be noted that out of ten parameters that are found to be sensitive to caspase-3 
production, only three out of four randomly chosen four parameters are varied. However, 
this small subset of parameter variations resulted in qualitative differences in all therapy 
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methods and quantitative differences in proteasome inhibitor therapy method. We 
speculate that although the apoptosis model used can explain healthy and unhealthy 
functioning of apoptosis, it is insufficient for designing and guiding cancer chemotherapy 
methods. We also speculate that if the current apoptosis model is further modified, and 
presently unknown more accurate values of the sensitive parameters are used while also 
including other hallmarks of cancer then, the resulting model may facilitate the decision 
of which chemotherapy drug or combinations of drugs to be used when treating patients 
with known cancer biomarkers. An interesting recent study by Spencer et al.
51
 suggested 
that a significant amount of cell-to-cell variability in TRAIL-induced apoptosis arises 
from natural differences in protein expression levels hence, not only due to differences in 
genotype. We plan to compare the contribution of this effect to the contribution of 
genotypic differences on resistance to treatments in a future computational study. 
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Figure legends 
 
Figure 1: Representation of healthy tissues that have homeostasis in cell number and 
unhealthy tissues that have cell accumulation. A. Phase plane for a mathematical model 
of apoptosis with suitable values of parameters that ensures bistability in response to 
apoptotic stimulus. B. Phase plane for an apoptosis model with parameter values that 
ensure monostable cell survival. 
 
Figure 2: Bifurcation diagram for mitochondria-dependent apoptosis model. The 
parameter values are those in parameter set 1 except for Apaf-1 production rate is 
decreased by 100 fold with respect to the nominal value. Inset: Enlargement of the lower 
portion of the diagram that depicts the limit points clearly. 
 
Figure 3: Model predictions for an apoptosis resistant cell that is treated by IAP and Bcl-
2 inhibitors. Model prediction of time evolutions of cyt c and caspase-3 concentrations 
when the apoptosis resistant cell is assumed to be treated by (A) an IAP inhibitor (steady 
state concentration of caspase-3 is 0.006 M) (B) a Bcl-2 inhibitor (steady state 
concentration of caspase-3 is 0.001 M). 
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Table 1. Sensitivity analysis of the parameters in mitochondria dependent apoptosis 
model. Steady-state values of caspase-3 when the parameters are perturbed are presented. 
  
Parameters 
 
[caspase-3] (nM) 
parameter value x 100 parameter value / 100 
kd 0 4827 
ΩApaf-1 7 0 
ΩIAP 0 5.4 
Ωprocaspase3 543 0 
Ωprocaspase9 47 0 
ΩBid 2.2 0 
ΩBcl2
o
 0 5.5 
ΩBax
o
 5.9 0 
Ωcytcmito 7 0 
p53 5.5 0 
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Table 2. The three parameter sets used in simulations of mitochondria-dependent 
apoptosis model 
 Parameter set 1 
Bagci et al. [3] 
model 
Parameter set 2 Parameter set 3 
ΩIAP 3x10
-2
 nM/s 4.5x10
-2
 nM/s 9x10
-2
 nM/s 
Ωprocaspase3 3x10
-1
 nM/s 3.6x10
-1
 nM/s 9x10
-1
 nM/s 
Ωprocaspase9 3x10
-1
 nM/s 2.85x10
-1
 nM/s 3x10
-1
 nM/s 
Ωcytcmito 3x10
-1
 nM/s 3x10
-1
 nM/s 1x10
-1
 nM/s 
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Table 3. Degradation rate constant range in which apoptosis occurs – possible outcomes 
of proteasome inhibitor treatment 
 
 
Deficiency in 
proapoptotic  
protein (nominal value 
multiplied by a factor) 
Parameter  
set 1 
Parameter  
set 2 
Parameter  
set 3 
ΩApaf-1 x 0.01 0 – L* x 0.35 s
-1
 0 - L x 0.35 s
-1
 0 -L x 0.27 s
-1
 
Ωprocaspase-3 x 0.01 0 – L x 0.31 s
-1
 0 - L x 0.33 s
-1
 0 - L x 0.53 s
-1
 
Ωprocaspase-9 x 0.01 0 – L x 0.42 s
-1
 0 - L x 0.43 s
-1
 0 - L x 0.50 s
-1
 
ΩBid x 0.01 0 – L x 0.88 s
-1
 0 - L x 0.89 s
-1
 0 - L x 0.79 s
-1
 
ΩBax x 0.01 0 – L x 0.42 s
-1
 0 - L x 0.42 s
-1
 0 - L x 0.36 s
-1
 
Ωcytcmito x 0.01 0 – L x 0.35 s
-1
 0 - L x 0.35 s
-1
 0 - L x 0.27 s
-1
 
ΩApaf-1 x 0.15 0 – L x 0.78 s
-1
 0 - L x 0.79 s
-1 0 - L x 0.62 s-1 
Ωprocaspase-3 x 0.15 0 – L x 0.95 s
-1
 0 -L x 0.97 s
-1 0 - L x 0.90 s-1 
Ωprocaspase-9 x 0.15 0 – L x 0.91 s
-1
 0 - L x 0.93 s
-1 0 - L x 0.81 s-1 
ΩBid x 0.15 Healthy cell Healthy cell 0 -L x 0.97 s
-1
 
ΩBax x 0.15 0 – L x 0.94 s
-1
 0 - L x 0.94 s
-1 0 - L x 0.81 s-1 
Ωcytcmito x 0.15 0 – L x 0.78 s
-1
 0 - L x 0.79 s
-1 0 - L x 0.62 s-1 
* L = 0.006 
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Table 4. The parameter sets used in simulations of mitochondria-dependent apoptosis 
model for statistical evaluation 
 
 Parameter set 1  
Bagci et al.
3
  
model  Variation 1A 
Parameter  
set 3  Variation 3A 
ΩIAP 2.85x10
-2
 nM/s 1.002x10
-1
 nM/s 
Ωprocaspase3 1.65x10
-1
 nM/s 7.77x10
-1
 nM/s 
Ωprocaspase9 4.59x10
-1
 nM/s 2.92x10
-1
 nM/s 
Ωcytcmito 3.54x10
-1
 nM/s 1.90x10
-1
 nM/s 
 Parameter set 1  
Bagci et al.
3
 
model  Variation 1B 
Parameter  
set 3  Variation 3B 
ΩIAP 2.803x10
-2
 nM/s 8.39x10
-2
 nM/s 
Ωprocaspase3 1.42x10
-1
 nM/s 9.13x10
-1
 nM/s 
Ωprocaspase9 3.29x10
-1
 nM/s 2.32x10
-1
 nM/s 
Ωcytcmito 4.54x10
-1
 nM/s 1.06x10
-1
 nM/s 
 Parameter set 1  
Bagci et al.
3
 
model  Variation 1C 
Parameter  
set 3  Variation 3C 
ΩIAP 3.82x10
-2
 nM/s 9.33x10
-2
 nM/s 
Ωprocaspase3 2.98x10
-1
 nM/s 8.86x10
-1
 nM/s 
Ωprocaspase9 3.17x10
-1
 nM/s 3.29x10
-1
 nM/s 
Ωcytcmito 3.11x10
-1
 nM/s 2.25x10
-1
 nM/s 
 Parameter set 1  
Bagci et al.
3
 
model  Variation 1D 
Parameter  
set 3  Variation 3D 
ΩIAP 1.66x10
-2
 nM/s 8.81x10
-2
 nM/s 
Ωprocaspase3 1.41x10
-1
 nM/s 1.07 nM/s 
Ωprocaspase9 3.71x10
-1
 nM/s 2.29x10
-1
 nM/s 
Ωcytcmito 2.84x10
-1
 nM/s 2.14x10
-1
 nM/s 
 Parameter set 1  
Bagci et al.
3
 
model  Variation 1E 
Parameter  
set 3  Variation 3E 
ΩIAP 2.41x10
-2
 nM/s 1.029x10
-1
 nM/s 
Ωprocaspase3 2.94x10
-1
 nM/s 8.85x10
-1
 nM/s 
Ωprocaspase9 2.31x10
-1
 nM/s 3.73x10
-1
 nM/s 
Ωcytcmito 2.60x10
-1
 nM/s 1.06x10
-1
 nM/s 
 Parameter set 1  
Bagci et al.
3
 
model  Variation 1F 
Parameter  
set 3  Variation 3F 
ΩIAP 4.19x10
-2
 nM/s 1.06x10
-1
 nM/s 
Ωprocaspase3 1.94x10
-1
 nM/s 9.57x10
-1
 nM/s 
Ωprocaspase9 5.18x10
-1
 nM/s 3.67x10
-1
 nM/s 
Ωcytcmito 2.17x10
-1
 nM/s 1.26x10
-1
 nM/s 
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Table 5. Degradation rate constant range in which apoptosis occurs for different sets of 
parameters around sets 1 and 3 – possible outcomes of proteasome inhibitor treatment 
 
Deficiency in 
proapoptotic  
protein (nominal 
value multiplied by a 
factor) 
Parameter set 1  
Variation 1A 
Variation 1B 
Variation 1C 
Variation 1D 
Varitation 1E 
Varitation 1F 
Parameter set 3 
Variation 3A 
Variation 3B 
Variation 3C 
Variation 3D 
Variation 3E 
Variation 3F 
Difference in means for 
 
90% confidence interval 
95% confidence interval 
99% confidence interval 
ΩApaf-1 x 0.01 
0.35 
0.36 
0.37 
0.35 
0.33 
0.32 
0.32 
0.27 
0.32 
0.26 
0.35 
0.33 
0.28 
0.29 
 
 
0.0060  ( 1- 2)  0.0633 
0.0019  ( 1- 2)  0.0698 
-0.0082  ( 1- 2)  0.0782 
Ωprocaspase-3 x 0.01 
0.31 
0.21 
0.19 
0.30 
0.19 
0.28 
0.25 
0.53 
0.49 
0.49 
0.54 
0.53 
0.55 
0.57 
 
 
0.2471  ( 1- 2)  0.3349 
0.2370  ( 1- 2)  0.3450 
0.2240  ( 1- 2)  0.3580 
Ωprocaspase-9 x 0.01 
0.42 
0.39 
0.33 
0.42 
0.35 
0.37 
0.43 
0.50 
0.53 
0.48 
0.58 
0.54 
0.53 
0.55 
 
 
0.0687  ( 1- 2)  0.2245 
0.0508  ( 1- 2)  0.2424 
0.0277  ( 1- 2)  0.2655 
ΩBid x 0.01 
0.88 
0.90 
0.90 
0.89 
0.85 
0.84 
0.85 
0.79 
0.86 
0.77 
0.90 
0.87 
0.80 
0.83 
 
 
-0.0016  ( 1- 2)  0.0684 
-0.0096  ( 1- 2)  0.0764 
-0.0199  ( 1- 2)  0.0867 
ΩBax x 0.01 
0.42 
0.43 
0.43 
0.41 
0.40 
0.39 
0.39 
0.36 
0.40 
0.35 
0.41 
0.40 
0.37 
0.38 
 
 
-0.0475  ( 1- 2)  0.0946 
-0.0638  ( 1- 2)  0.1104 
-0.0848  ( 1- 2)  0.1314 
Ωcytcmito x 0.01 
0.35 
0.36 
0.37 
0.35 
0.33 
0.32 
0.32 
0.27 
0.32 
0.32 
0.35 
0.33 
0.28 
0.29 
 
 
0.0024  ( 1- 2)  0.0510 
-0.0023  ( 1- 2)  0.0557 
-0.0103  ( 1- 2)  0.0637 
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ΩApaf-1 x 0.15 
0.78 
0.82 
0.83 
0.79 
0.74 
0.72 
0.74 
0.62 
0.73 
0.60 
0.79 
0.75 
0.64 
0.68 
 
 
0.0114  ( 1- 2)  0.1386 
-0.0032  ( 1- 2)  0.1532 
-0.0220  ( 1- 2)  0.1720 
Ωprocaspase-3 x 0.15 
0.95 
0.91 
0.78 
0.96 
0.79 
0.87 
0.93 
0.90 
Healthy cell 
0.88 
Healthy cell 
Healthy cell 
0.94 
0.98 
 
Ωprocaspase-9 x 0.15 
0.91 
0.91 
0.81 
0.92 
0.81 
0.83 
0.89 
0.81 
0.93 
0.79 
Healthy cell 
0.95 
0.84 
0.88 
 
ΩBid x 0.15 
Healthy cell 
Healthy cell  
Healthy cell 
Healthy cell 
Healthy cell 
Healthy cell 
Healthy cell 
0.97 
Healthy cell 
0.95 
Healthy cell 
Healthy cell 
Healthy cell 
Healthy cell 
 
ΩBax x 0.15 
0.94 
0.96 
0.75 
0.94 
0.90 
0.88 
0.90 
0.81 
0.90 
0.79 
0.94 
0.91 
0.84 
0.86 
 
 
-0.0520  ( 1- 2)  0.0820 
-0.0674  ( 1- 2)  0.0974 
-0.0873  ( 1- 2)  0.1173 
Ωcytcmito x 0.15 
0.78 
0.82 
0.65 
0.79 
0.74 
0.72 
0.74 
0.62 
0.73 
0.60 
0.79 
0.75 
0.64 
0.68 
 
 
-0.024  ( 1- 2)  0.01140 
-0.0399  ( 1- 2)  0.1299 
-0.0603  ( 1- 2)  0.1503 
 
* L = 0.006 
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Table 6. Bcl-2 production rate constant range in which apoptosis occurs and possible 
other outcomes of Bcl-2 inhibitor treatment 
 
Deficiency in 
proapoptotic  
protein (nominal 
value multiplied by 
a factor) 
Parameter  
set 1 
Parameter  
set 2 
Parameter  
set 3 
ΩApaf-1 x 0.01 
x * 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
 [caspase-3] = 0 nM 
Ωprocaspase-3 x 0.01 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
Ωprocaspase-9 x 0.01 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
ΩBid x 0.01 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
ΩBax x 0.01 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
Ωcytcmito x 0.01 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
ΩApaf-1 x 0.15 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
Ωprocaspase-3 x 0.15 
x 
[caspase-3] = 0.80nM 
x 
[caspase-3] = 0.92nM 
x 
[caspase-3] = 0 nM 
Ωprocaspase-9 x 0.15 
x  
[caspase-3] = 0.52nM 
x 
[caspase-3] = 0.59nM 
x 
[caspase-3] = 0 nM 
ΩBid x 0.15 Healthy cell Healthy cell 
x 
[caspase-3] = 0 nM 
ΩBax x 0.15 0–3x10
-2
x0.10 nM/s 0–3x10-2x0.21 nM/s 
x 
[caspase-3] = 0 nM 
Ωcytcmito x 0.15 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
* x: Apoptosis impossible 
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Table 7. Possible outcomes of IAP inhibitor treatment 
 
Deficiency in 
proapoptotic  
protein (nominal 
value multiplied by 
a factor) 
Parameter  
set 1 
Parameter  
set 2 
Parameter  
set 3 
ΩApaf-1 x 0.01 
x * 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
Ωprocaspase-3 x 0.01 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
Ωprocaspase-9 x 0.01 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
ΩBid x 0.01 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
ΩBax x 0.01 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
Ωcytcmito x 0.01 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
ΩApaf-1 x 0.15 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
Ωprocaspase-3 x 0.15 
x  
[caspase-3]=0.79 nM 
x 
[caspase-3]=0.90 nM 
x 
[caspase-3] = 0 nM 
Ωprocaspase-9 x 0.15 
x 
[caspase-3]=0.48 nM 
x 
[caspase-3]=0.55 nM 
x 
[caspase-3] = 0 nM 
ΩBid x 0.15 Healthy cell Healthy cell 
x 
[caspase-3] = 0 nM 
ΩBax x 0.15 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
Ωcytcmito x 0.15 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
* x: Apoptosis impossible 
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Table 8. Bcl-2 production rate constant range in which apoptosis occurs and possible 
other outcomes of Bcl-2 inhibitor treatment obtained for different sets of parameters 
around sets 1 and 3. 
 
Deficiency in proapoptotic  
protein (nominal value multiplied by a 
factor) 
Parameter set 1 
Variation 1A 
Variation 1B 
Variation 1C 
Variation 1D 
Variation 1E 
Variation 1F 
Parameter set 3 
Variation 3A 
Variation 3B 
Variation 3C 
Variation 3D 
Variation 3E 
Variation 3F 
ΩApaf-1 x 0.01 
x * [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
Ωprocaspase-3 x 0.01 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
Ωprocaspase-9 x 0.01 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
ΩBid x 0.01 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
ΩBax x 0.01 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
Ωcytcmito x 0.01 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
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ΩApaf-1 x 0.15 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
Ωprocaspase-3 x 0.15 
x [caspase-3] = 0.80nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0.48 nM 
x [caspase-3] = 0.86 nM 
x [caspase-3] = 0.44 nM 
x [caspase-3] = 0.52 nM 
x [caspase-3] = 0.72 nM 
x [caspase-3] = 0 nM 
Healthy cell 
x [caspase-3] = 0 nM 
Healthy cell 
Healthy cell 
x [caspase-3] = 0.48 nM 
x [caspase-3] = 0.95 nM 
Ωprocaspase-9 x 0.15 
x [caspase-3] = 0.52nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0.43 nM 
x [caspase-3] = 0.60 nM 
x [caspase-3] = 0.26 nM 
x [caspase-3] = 0.18 nM 
x [caspase-3] = 0.37 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
Healthy cell 
x [caspase-3] = 0.59 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
ΩBid x 0.15 
Healthy cell 
Healthy cell 
Healthy cell 
Healthy cell 
Healthy cell 
Healthy cell 
Healthy cell 
x [caspase-3] = 0 nM 
Healthy cell 
x [caspase-3] = 0 nM 
Healthy cell 
Healthy cell  
Healthy cell  
Healthy cell 
ΩBax x 0.15 
0–3x10-2x0.10 nM/s 
x [caspase-3] = 0 nM 
0–3x10-2x0.59 nM/s 
0–3x10-2x0.29 nM/s 
x [caspase-3] = 0.54 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0.43 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0.80 nM 
Healthy cell  
x [caspase-3] = 0 nM 
Ωcytcmito x 0.15 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
x [caspase-3] = 0 nM 
             * x: Apoptosis impossible 
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Table 9. Possible outcomes of Bid-like synthetic peptides treatment 
Deficiency in 
proapoptotic  
protein (nominal 
value multiplied 
by a factor) 
Parameter 
group 1 
Parameter 
group 2 
Parameter 
group 3 
ΩApaf-1 x 0.01 
x * 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
X 
[caspase-3] = 0 nM 
Ωprocaspase-3 x 0.01 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
X 
[caspase-3] = 0 nM 
Ωprocaspase-9 x 0.01 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
X 
[caspase-3] = 0 nM 
ΩBax x 0.01 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
X 
[caspase-3] = 0 nM 
Ωcytcmito x 0.01 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
X 
[caspase-3] = 0 nM 
ΩApaf-1 x 0.15 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
X 
[caspase-3] = 0 nM 
Ωprocaspase-3 x 0.15 
x 
[caspase-3] = 0.78nM 
x 
[caspase-3] =  0.88nM 
X 
[caspase-3] = 0.32nM 
Ωprocaspase-9 x 0.15 
x 
[caspase-3] = 0.53nM 
x 
[caspase-3] = 0.59nM 
X 
[caspase-3] = 0 nM 
ΩBax x 0.15 
x 
[caspase-3] = 0.21nM 
x 
[caspase-3] = 0.22nM 
X 
[caspase-3] = 0 nM 
Ωcytcmito x 0.15 
x 
[caspase-3] = 0 nM 
x 
[caspase-3] = 0 nM 
X 
[caspase-3] = 0 nM 
* x: Apoptosis impossible 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 47 
 
  
Table 10. Comparison of the results from Figure 7A in paper by di Pietro et al.
30
 and the 
present simulation results. 
 
 
 Casp3 Casp9 Bax Bcl-2 Bid Apaf-1 Theoretical Apoptotic 
response 
Leukaemia 0 0 + + - - Monostable cell survival 
neuroblastoma 0 - + + + - Monostable cell survival 
Breast - 0 0 + 0 0 Monostable cell survival 
Colon 0 0 0 0 0 0 [caspase-3]=5.4 nM 
Ovary (x0.15) 0 + 0 0 0 [caspase-3]=0.9 nM 
Kidney 0 + 0 - 0 0 [caspase-3]=14.7 nM 
Skin 0 0 0 0 + 0 [caspase-3]=5.4 nM 
Prostate -   0 0 0 0 0 Monostable cell survival 
Pancreas 0 0 + + + + [caspase-3]=20.7 nM 
Stomach + 0 + 0 0 0 [caspase-3]=17.3 nM 
Lung 0 + + 0 - 0 [caspase-3]=15.1 nM 
Liver 0 0 0 0 - 0 Monostable cell survival 
Thyroid 0 0 0 0 0 0 [caspase-3]=5.4 nM 
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Supplementary Table 1. The chemical reactions and physical interactions used in 
mitochondria-dependent apoptosis model (originally proposed by [1])*. 
 
Binding-unbinding interactions, catalytic reactions Reactions of formation (or 
production) and degradation of 
proteins 
casp8 + Bid ↔ casp8_Bid mRNA → Apaf-1 
casp8_Bid → casp8 + tBid mRNA → IAP 
tBid → tBidmito mRNA → procaspase-3 
tBidmito + Bax → tBid_Baxmito  mRNA → procaspase-9 
tBid.Baxmito + Bax → tBid + (Baxmito)2 mRNA → Bid 
(Baxmito)2 + cytcmito → (Baxmito)2 + cytc mRNA → Bcl-2 
Bcl-2 + Bax → Bcl-2.Bax  mRNA → Bax 
cyt c + Apaf-1 ↔ cytc.Apaf-1  mRNA → mitochondrial cyt c 
7 cytc.Apaf-1 ↔ apop casp8 → aminoacids 
apop + procasp9 ↔ apop.procasp9 Bid → aminoacids 
Apop.procasp9 + procasp9 ↔ apop.(procasp9)2 tBid → aminoacids 
Apop.(procasp9)2 → apop.(casp9)2  tBidmito → aminoacids  
Apop.(casp9)2 ↔ apop.casp9 + casp9 tBid_Baxmito → aminoacids  
Apop.casp9 ↔ apop + casp9 Bax → aminoacids 
casp9 + IAP ↔ casp9.IAP (Baxmito)2 → aminoacids 
Apop.casp9 + IAP ↔ apop.casp9.IAP cytcmito → aminoacids 
Apop.(casp9)2 + IAP ↔ apop.(casp9)2.IAP cytc → aminoacids 
procasp3 + casp9 ↔ procasp3.casp9 Bcl-2 → aminoacids 
procasp3.casp9 → casp3 + casp9 Apaf-1 → aminoacids 
procasp3 +  apop.(casp9)2 ↔ procasp3.apop.(casp9)2 procasp9 → aminoacids 
procasp3.apop.(casp9)2 → casp3 + apop.(casp9)2 casp9 → aminoacids 
casp3 + IAP ↔ casp3.IAP IAP → aminoacids 
casp3 + Bid ↔ cap3.Bid procasp3 → aminoacids 
cap3.Bid → casp3 + tBid casp3 → aminoacids 
casp3 + Bcl-2 ↔ cap3.Bcl-2 Bcl-2cleaved → aminoacids  
cap3.Bcl-2 → casp3 + Bcl-2cleaved   
*p53 increases Bax formation rate and decreases Bcl-2 formation rate [3]. 
 
 
 
Reference 1. Bagci EZ, Vodovotz Y, Billiar TR, Ermentrout GB, Bahar I (2006) 
Bistability in apoptosis: Roles of Bax, Bcl-2 and Mitochondrial Permeability Transition 
Pores. Biophys J 90: 1546-1559. 
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Figure 1 
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Figure 2 
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Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
